A Randomized Study With Oral Melphalan + Prednisone (MP) Versus Melphalan, + Prednisone + Thalidomide (MPT) for Newly Diagnosesd Elderly Patients With Multiple Myeloma

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the study is to compare efficacy and toxicity of melphalan and prednisone versus meplhalan, prednisone and Thalidomide in elderly patients with multiple myeloma or patients with multiple myeloma but not eligible for high dose treatment with stem cells support.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gruppo Italiano Studio Linfomi
• Treatments: Melphalan; Prednisone; Thalidomide

Criteria

Inclusion Criteria:

• newly diagnosed of multiple myeloma.

• Age > 65 years

• ECOG <= 3

• Written informed consent given at the time of randomization

• Patients with age <= 65 but not eligible for high dose treatment with stem cells support

Exclusion Criteria:

• ECOG > 3

• current neoplasm..

• contraindications to use thalidomide

• peripheral neurophaty